Tenofovir EMT (GH)


What it is used for

Treatment of HIV-1 infection TENOFOVIR EMT GH is indicated for the treatment of HIV infected adults over the age of 18 years, in combination with other antiretroviral agents.,Pre-Exposure Prophylaxis TENOFOVIR EMT GH is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples (see CLINICAL STUDIES).


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 25 degrees Celsius
  • Shelf lifetime is 24 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 25 degrees Celsius
  • Shelf lifetime is 24 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Pregnant or planning a pregnancy?

For the active ingredient tenofovir disoproxil + emtricitabine

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.


Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.


Visual appearance

Blue, oval-shaped, biconvex, film-coated tablets plain on both sides.

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments